| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
ctDNA as a predictive biomarker in advanced breast cancer: Lessons from the MONALEESA studies
|
Agostinetto, E.
|
|
|
34 |
11 |
p. 955-959
|
artikel
|
| 2 |
Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials
|
Taieb, J.
|
|
|
34 |
11 |
p. 1025-1034
|
artikel
|
| 3 |
Editorial Board
|
|
|
|
34 |
11 |
p. iii
|
artikel
|
| 4 |
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma☆
|
Rosenberg, J.E.
|
|
|
34 |
11 |
p. 1047-1054
|
artikel
|
| 5 |
HER2-low expression in patients with advanced or metastatic solid tumors
|
Uzunparmak, B.
|
|
|
34 |
11 |
p. 1035-1046
|
artikel
|
| 6 |
High incidence of cytokine release syndrome in patients with advanced NSCLC treated with nivolumab plus ipilimumab
|
Shiraishi, Y.
|
|
|
34 |
11 |
p. 1064-1065
|
artikel
|
| 7 |
Moving towards tissue-agnostic antibody drug conjugates: HER2 expression as the poster child
|
Abelman, R.
|
|
|
34 |
11 |
p. 968-969
|
artikel
|
| 8 |
Off-target resistance to larotrectinib in two patients with NTRK fusion-positive pediatric solid tumors
|
Lu, S.
|
|
|
34 |
11 |
p. 1065-1067
|
artikel
|
| 9 |
Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial
|
Nilsson, K.
|
|
|
34 |
11 |
p. 1015-1024
|
artikel
|
| 10 |
Optimizing the potential of antibody–drug conjugates in oncology
|
Mosele, F.
|
|
|
34 |
11 |
p. 964-967
|
artikel
|
| 11 |
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Conroy, T.
|
|
|
34 |
11 |
p. 987-1002
|
artikel
|
| 12 |
Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas
|
Song, Y.
|
|
|
34 |
11 |
p. 1055-1063
|
artikel
|
| 13 |
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
|
André, F.
|
|
|
34 |
11 |
p. 1003-1014
|
artikel
|
| 14 |
Standard versus prolonged intervals to surgery in resectable esophageal cancer: does timing matter?
|
Derks, S.
|
|
|
34 |
11 |
p. 960-961
|
artikel
|
| 15 |
Table of Contents
|
|
|
|
34 |
11 |
p. i-ii
|
artikel
|
| 16 |
Time to start testing KRAS and BRAF V600E mutations in stage III colon cancer? Not in routine care, yet in clinical trials
|
Dienstmann, R.
|
|
|
34 |
11 |
p. 962-963
|
artikel
|
| 17 |
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
|
Curigliano, G.
|
|
|
34 |
11 |
p. 970-986
|
artikel
|
Tijdschrift beschrijving